Group items tagged

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot InitiativeSM that is intended to accelerate cancer research. The purpose of this FOA is to promote research on developing the descriptive, inferential, and graphical statistical methods for data generated in clinical trials including Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) items. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Accelerate research that can identify approaches to monitor and manage patient-reported symptoms.

The purpose of this FOA is to invite applications that investigate aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in this system and its organs, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. However, studies with the major focus on immune mechanisms, role of lymphatics in cancer metastasis and study of lymphatic vessels in organs other than those from the digestive system will not be considered responsive.

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

Millions of people with HIV/AIDS now have extended life spans as a result of targeted HIV testing services and scale-up of effective anti-retroviral therapy (ART), resulting in increased need to 1) effectively manage large volumes of data; 2) accurately track patient cohorts across space and time; 3) track utilization of human and material resources; and 4) support evidence-driven decisions. Interoperable health information systems (HIS), including electronic medical records (EMR) and laboratory information systems (LIS), are essential tools for collecting, managing, and using these data. This NOFO will support countries to 1) design, develop, implement, and evaluate HIS; 2) develop and improve policy, governance, and infrastructure needed to implement HIS and increase sustainability and country ownership; 3) sustain informatics workforce and capacity development; and 4) protect, secure, standardize, exchange, and share data to improve health.

The Ohio Affiliate of  Prevent Blindness is accepting applications for its 2018 Young Investigator Student Fellowship Awards for Female Scholars in Vision Research. The Fellowship Program is designed to provide support for outstanding female scientists committed to pursuing biomedical, behavioral or clinical research careers relevant to the mission of Prevent Blindness - to prevent blindness and preserve sight.  Grants will be awarded for the summer 2018 session.  Awards will range from $3000-$5000 depending upon the availability of funds. The deadline for receipt of applications is Feb. 15, 2018. Applicants must be post-baccalaureate students enrolled in a master's or doctorate program during the summer of 2018, female, citizens or permanent residents of the United States, and conducting their research with a recognized academic institution in the State of Ohio. Applications from diverse fields in the health sciences including, but not limited to ophthalmology, optometry, nursing, genetics, public health, nutrition, gerontology, and bioengineering, are appropriate to the goals of this fellowship award. The Ohio Affiliate of Prevent Blindness encourages fellowship applications which investigate public health issues related to the burden of eye-related health and safety topics.

The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.

The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Innovation Research (SBIR) program to advance the field of neuroscience research. This FOA specifically supports the development of novel neurotechnologies as well as the translation of technologies developed through the BRAIN initiative or through other funding programs, towards commercialization. Funding can support the iterative refinement of these tools and technologies with the end-user community, with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience research.

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Artificial Intelligence (AI) has advanced tremendously and today promises personalized healthcare; enhanced national security; improved transportation; and more effective education, to name just a few benefits. Increased computing power, the availability of large datasets and streaming data, and algorithmic advances in machine learning (ML) have made it possible for AI development to create new sectors of the economy and revitalize industries. Continued advancement, enabled by sustained federal investment and channeled toward issues of national importance, holds the potential for further economic impact and quality-of-life improvements.